Sichuan Medco Pharmaceutical Stock Co., Ltd.

Main purpose: This study used sacubitril valsartan sodium tablets produced by Sichuan Meidakang Pharmaceutical Co., Ltd. as the test preparation and sacubitril valsartan sodium tablets (trade name: Nuxintu) certified by Novartis Pharma Schweiz AG as the reference preparation to conduct a human bioequivalence test under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose: This study used dapagliflozin metformin sustained-release tablets developed by Sichuan Meidakang Pharmaceutical Co., Ltd. as the test preparation. According to the relevant provisions of the bioequivalence test, Xigduo XR certified by AstraZeneca AB was used as the reference preparation. The human bioequivalence test was conducted under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose: This study uses azithromycin dispersible tablets (specification: 0.25g) certified by Sichuan Meidakang Pharmaceutical Co., Ltd. as the test preparation, and azithromycin tablets (trade name: AZITROMYCINE 250MG TEVA, specification: 250mg) certified by Teva Nederland B.V. as the reference preparation according to the relevant provisions of the bioequivalence test. Human bioequivalence tests are conducted under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.